Drama, thy name is Amarin.
If you want to get a rise out of investors who have been following Amarin, the maker of the fish-oil-derived heart drug Vascepa, try mentioning the name of Cleveland Clinic cardiologist Dr. Steven Nissen.
That’s what Jefferies analyst Michael Yee did in a “tidbit” that came 12 minutes and 30 seconds into his podcast for investors, saying Nissen “has been writing correspondence with the FDA over the past six to 12 months.” Yee said that he had tried to use the Freedom of Information Act to get Nissen’s emails, but that they would not be coming any time soon. He said he didn’t know what Nissen might want, but noted that Nissen is the lead investigator for a large study of a competing product, AstraZeneca’s Epanova.
About the Author Reprints
Good article